9
Participants
Start Date
September 9, 2017
Primary Completion Date
April 30, 2022
Study Completion Date
April 30, 2022
Ceritinib
"ALK tyrosine inhibitor, 300 mg - 450 mg PO daily.~Phase I dose escalation:~1. Ceritinib 300mg~2. Ceritinib 450mg~3. Ceritinib 450mg~The Phase II doses will be determined by Phase I dose escalation study"
Trametinib
"MEK kinase inhibitor, 1.5 mg - 2.0 mg PO daily.~Phase I dose escalation:~1. Trametinib 1.5mg~2. Trametinib 1.5mg~3. Trametinib 2.0mg~The Phase II doses will be determined by Phase I dose escalation study"
University of California, San Francisco, San Francisco
University of California, Davis, Davis
Collaborators (1)
Novartis Pharmaceuticals
INDUSTRY
University of California, Davis
OTHER
University of California, San Francisco
OTHER